Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective concentration (EC90). Clinical Trials Registration. NCT00825929. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Citation

Vera Bukkems, Coca Necsoi, Carmen Hidalgo Tenorio, Coral Garcia, Jürgen Rockstroh, Caroline Schwarze-Zander, John S Lambert, David Burger, Deborah Konopnicki, Angela Colbers. Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Dec 17;71(10):e714-e717

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32330231

View Full Text